NCT06466655Completed
Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline
Accelerated Vascular Aging in Midlife as a Mechanism Linking Daily Stress to Cognitive Decline
Source: ClinicalTrials.gov · Last updated 2 Oct 2025
Brief summary (registry, in English)
The goal of this pilot clinical trial is to begin to understand how day-to-day stress affects cardiovascular health and brain function in middle-aged adults. The main question aims to answer is whether the link between daily stress and vascular dysfunction is a potential mechanism of increased risk for future cognitive decline. Participants will complete a 15-day testing cycle. During this cycle, participants will complete daily assessments of stress using an online survey tool for 14-consecutive days. On the last day of each cycle, vascular function will be assessed during a laboratory visit.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 17 (actual)
- First submitted
- 4 Jun 2024
- Start date
- 30 May 2024
- Primary completion date
- 10 Apr 2025
- Lead sponsor
- University of Delaware
- Diseases
- Depression
- NCT number
- NCT06466655
What you commit to
- Study type: Interventional
- Participants enrolled: 17
- From 30 May 2024 to the primary completion date, 10 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or recent use (within 8 wks) of medications that alter cardiovascular function or psychoactive/psychopharmacological drugs
- Current or past use of hormone replacement therapy
Other illness
- Psychiatric illness aside from MDD (e.g., bipolar disorder, schizophrenia, eating disorders), assessed by the MINI and self-report
- Objective cognitive impairment (\<26 on the Montreal Cognitive Assessment)
- Diagnosed or unstable neurocognitive, cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological diseases
- Allergy to study drugs or pharmacological agents
Lab values
- HbA1c ≥5.7%
Age
- \<40 or \>55 yrs
- Females who are pregnant, breastfeeding, or planning to become pregnant; female subjects of child-bearing age must have a negative urine pregnancy test on the day of all experimental visits
Other
- Subjects will be excluded at the discretion of the PI/collaborating clinicians or for any of the following reasons:
- Body mass index ≥35 kg/m2
- Resting systolic BP ≥140 mmHg
- Direct low-density lipoprotein ≥160mg/dl
- Tobacco use (including electronic cigarettes)
Who the study is looking for
- Males and females aged 40-55 yrs
- Absence of objective cognitive impairment (≥26 on the Montreal Cognitive Assessment)
- Absence of diagnosed or unstable neurocognitive, cardiovascular, metabolic, renal, hepatic, autonomic, autoimmune, or dermatological diseases, as determined by medical history, physical examination, blood chemistries, and 12-lead resting electrocardiogram
- Participants must have a level of understanding of the English language sufficient to provide informed consent and to agree to all tests and procedures, as well as the capacity and willingness to attend all study related visits and to comply with the study protocol
Age in the registry: 40 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Delaware Coordinator of this site? Confirm its status | Newark | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.